ONO-2506 inhibits spike-wave discharges in a genetic animal model without affecting traditional convulsive tests via gliotransmission regulation

British Journal of Pharmacology

Volumn 168, Issue 5, 2013, Pages 1088-1100

  Yamamura, Satoshi ^a   Hoshikawa, Masamitsu ^b   Dai, Kato ^c   Saito, Hiromitsu ^a   Suzuki, Noboru ^a   Niwa, Osamu ^c   Okada, Motohiro ^a  

^a MIE UNIVERSITY   (Japan)

^b ONO PHARMACEUTICAL CO   (Japan)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

anticonvulsant; antiepileptic drug; astrocyte; kynurenic acid; microdialysis; ONO 2506

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; ARUNDIC ACID; FLUOROCITRIC ACID; GLUTAMIC ACID; KYNURENIC ACID; SERINE; TETANUS TOXIN; TETRODOTOXIN;

ABSENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASTROCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEPOLARIZATION; DOSE RESPONSE; EPILEPTIC DISCHARGE; EXOCYTOSIS; GENETIC MODEL; GLIA; GLIA CELL; MALE; MOUSE; MOUSE STRAIN; NERVE CELL STIMULATION; NEUROMODULATION; NEUROTRANSMITTER RELEASE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN SECRETION; RAT; SEIZURE; SPIKE WAVE; SYNAPTIC TRANSMISSION;

ANIMALS; ANTICONVULSANTS; ASTROCYTES; CAPRYLATES; CELLS, CULTURED; CONVULSANTS; DISEASE MODELS, ANIMAL; ELECTROSHOCK; EPILEPSY; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; KYNURENIC ACID; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PENTYLENETETRAZOLE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SERINE; SYNAPTIC TRANSMISSION;

EID: 84874256787     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02132.x     Document Type: Article

References (59)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-324.
2. Asano T, Mori T, Shimoda T, Shinagawa R, Satoh S, Yada N, et al. (2005). Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. Curr Drug Targets CNS Neurol Disord 4: 127-142.
3. Blume W, (2007). Drug-resistant epilepsy. In:, Engel J, Jr, Pedley T, (eds). Epilepsy: A Comprehensive Text Book, Vol. 2. Lippincott Williams & Wilkins: Philadelphia, PA, pp. 1365-1400.
4. Blumenfeed H, Coulter D, (2007). Thalamocortical anatomy and physiology. In:, Engel J, Jr, Pedley T, (eds). Epilepsy: A Comprehensive Text Book, Vol. 2. Lippincott Williams & Wilkins: Philadelphia, PA, pp. 353-366.
5. Bouwman BM, van Rijn CM, (2004). Effects of levetiracetam on spike and wave discharges in WAG/Rij rats. Seizure 13: 591-594.
6. De Smedt T, Raedt R, Vonck K, Boon P, (2007). Levetiracetam: the profile of a novel anticonvulsant drug-part I: preclinical data. CNS Drug Rev 13: 43-56.
7. Depaulis A, van Luijtelaar G, (2006). Genetic models of absence epilepsy in the rat. In:, Pitkanen A, Schwartzkroin P, Moshe S, (eds). Models of Seizures and Epilepsy. Elsevier: San Diego, CA, pp. 233-248.
8. Errington AC, Cope DW, Crunelli V, (2011). Augmentation of tonic GABA(A) inhibition in absence epilepsy: therapeutic value of inverse agonists at extrasynaptic GABA(A) receptors. Adv Pharmacol Sci 2011: 790590.
9. Fellin T, Haydon PG, (2005). Do astrocytes contribute to excitation underlying seizures? Trends Mol Med 11: 530-533.
10. Gower AJ, Noyer M, Verloes R, Gobert J, Wulfert E, (1992). ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 222: 193-203.
11. Gower AJ, Hirsch E, Boehrer A, Noyer M, Marescaux C, (1995). Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 22: 207-213.
12. Griffin WS, Yeralan O, Sheng JG, Boop FA, Mrak RE, Rovnaghi CR, et al. (1995). Overexpression of the neurotrophic cytokine S100 beta in human temporal lobe epilepsy. J Neurochem 65: 228-233.
13. Gurbanova AA, Aker R, Berkman K, Onat FY, van Rijn CM, van Luijtelaar G, (2006). Effect of systemic and intracortical administration of phenytoin in two genetic models of absence epilepsy. Br J Pharmacol 148: 1076-1082.
14. Halassa MM, Fellin T, Haydon PG, (2007). The tripartite synapse: roles for gliotransmission in health and disease. Trends Mol Med 13: 54-63.
15. Hamilton NB, Attwell D, (2010). Do astrocytes really exocytose neurotransmitters? Nat Rev Neurosci 11: 227-238.
16. Kaminski RM, Zielinska E, Dekundy A, van Luijtelaar G, Turski W, (2003). Deficit of endogenous kynurenic acid in the frontal cortex of rats with a genetic form of absence epilepsy. Pol J Pharmacol 55: 741-746.
17. Kato D, Sekioka N, Ueda A, Kurita R, Hirono S, Suzuki K, et al. (2008). A nanocarbon film electrode as a platform for exploring DNA methylation. J Am Chem Soc 130: 3716-3717.
18. Kato D, Komoriya M, Nakamoto K, Kurita R, Hirono S, Niwa O, (2011). Electrochemical determination of oxidative damaged DNA with high sensitivity and stability using a nanocarbon film. Anal Sci 27: 703-705.
19. Lee M, McGeer EG, McGeer PL, (2011). Mechanisms of GABA release from human astrocytes. Glia 59: 1600-1611.
20. Lee TS, Mane S, Eid T, Zhao H, Lin A, Guan Z, et al. (2007). Gene expression in temporal lobe epilepsy is consistent with increased release of glutamate by astrocytes. Mol Med 13: 1-13.
21. Loscher W, Honack D, (1993). Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 232: 147-158.
22. van Luijtelaar G, (2011). The prevention of behavioral consequences of idiopathic generalized epilepsy: evidence from rodent models. Neurosci Lett 497: 177-184.
23. Luttjohann A, Fabene PF, van Luijtelaar G, (2009). A revised Racine's scale for PTZ-induced seizures in rats. Physiol Behav 98: 579-586.
24. Mandhane SN, Aavula K, Rajamannar T, (2007). Timed pentylenetetrazol infusion test: a comparative analysis with s.c.PTZ and MES models of anticonvulsant screening in mice. Seizure 16: 636-644.
25. McGrath J, Drummond G, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
26. Meeren HK, Pijn JP, Van Luijtelaar EL, Coenen AM, Lopes da Silva FH, (2002). Cortical focus drives widespread corticothalamic networks during spontaneous absence seizures in rats. J Neurosci 22: 1480-1495.
27. Meldrum B, (2007). Molecular targets for novel antiepileptic drugs. In:, Engel J, Jr, Pedley T, (eds). Epilepsy: A Comprehensive Text Book, Vol. 2. Lippincott Williams & Wilkins: Philadelphia, PA, pp. 1457-1468.
28. Mori T, Town T, Tan J, Yada N, Horikoshi Y, Yamamoto J, et al. (2006). Arundic Acid ameliorates cerebral amyloidosis and gliosis in Alzheimer transgenic mice. J Pharmacol Exp Ther 318: 571-578.
29. Mothet JP, Pollegioni L, Ouanounou G, Martineau M, Fossier P, Baux G, (2005). Glutamate receptor activation triggers a calcium-dependent and SNARE protein-dependent release of the gliotransmitter d-serine. Proc Natl Acad Sci USA 102: 5606-5611.
30. Murakami T, Okada M, Kawata Y, Zhu G, Kamata A, Kaneko S, (2001). Determination of effects of antiepileptic drugs on SNAREs-mediated hippocampal monoamine release using in vivo microdialysis. Br J Pharmacol 134: 507-520.
31. Niwa O, Jia J, Sato Y, Kato D, Kurita R, Maruyama K, et al. (2006). Electrochemical performance of angstrom level flat sputtered carbon film consisting of sp2 and sp3 mixed bonds. J Am Chem Soc 128: 7144-7145.
32. Ohoyama K, Yamamura S, Hamaguchi T, Nakagawa M, Motomura E, Shiroyama T, et al. (2011). Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur J Pharmacol 653: 47-57.
33. Ohtani R, Tomimoto H, Wakita H, Kitaguchi H, Nakaji K, Takahashi R, (2007). Expression of S100 protein and protective effect of arundic acid on the rat brain in chronic cerebral hypoperfusion. Brain Res 1135: 195-200.
34. Okada M, Nutt DJ, Murakami T, Zhu G, Kamata A, Kawata Y, et al. (2001). Adenosine receptor subtypes modulate two major functional pathways for hippocampal serotonin release. J Neurosci 21: 628-640.
35. Okada M, Yoshida S, Zhu G, Hirose S, Kaneko S, (2005). Biphasic actions of topiramate on monoamine exocytosis associated with both soluble N-ethylmaleimide-sensitive factor attachment protein receptors and Ca(2+)-induced Ca(2+)-releasing systems. Neuroscience 134: 233-246.
36. Oki C, Watanabe Y, Yokoyama H, Shimoda T, Kato H, Araki T, (2008). Delayed treatment with arundic acid reduces the MPTP-induced neurotoxicity in mice. Cell Mol Neurobiol 28: 417-430.
37. Otoul C, Arrigo C, van Rijckevorsel K, French JA, (2005). Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 28: 72-78.
38. Parpura V, Zorec R, (2010). Gliotransmission: exocytotic release from astrocytes. Brain Res Rev 63: 83-92.
39. Peeters BW, Ramakers GM, Vossen JM, Coenen AM, (1994). The WAG/Rij rat model for nonconvulsive absence epilepsy: involvement of nonNMDA receptors. Brain Res Bull 33: 709-713.
40. Pinault D, (2003). Cellular interactions in the rat somatosensory thalamocortical system during normal and epileptic 5-9 Hz oscillations. J Physiol 552 (Pt 3): 881-905.
41. Potter MC, Elmer GI, Bergeron R, Albuquerque EX, Guidetti P, Wu HQ, et al. (2010). Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 35: 1734-1742.
42. Rothermundt M, Peters M, Prehn JH, Arolt V, (2003). S100B in brain damage and neurodegeneration. Microsc Res Tech 60: 614-632.
43. Saito H, Okada M, Miki T, Wakamori M, Futatsugi A, Mori Y, et al. (2009). Knockdown of Cav2.1 calcium channels is sufficient to induce neurological disorders observed in natural occurring Cacna1a mutants in mice. Biochem Biophys Res Commun 390: 1029-1033.
44. Schell MJ, Molliver ME, Snyder SH, (1995). d-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release. Proc Natl Acad Sci USA 92: 3948-3952.
45. Seifert G, Schilling K, Steinhauser C, (2006). Astrocyte dysfunction in neurological disorders: a molecular perspective. Nat Rev Neurosci 7: 194-206.
46. Severino PC, Muller Gdo A, Vandresen-Filho S, Tasca CI, (2011). Cell signaling in NMDA preconditioning and neuroprotection in convulsions induced by quinolinic acid. Life Sci 89: 570-576.
47. Shapiro LA, Wang L, Ribak CE, (2008). Rapid astrocyte and microglial activation following pilocarpine-induced seizures in rats. Epilepsia 49 (Suppl. 2): 33-41.
48. Sitnikova E, Kulikova S, Birioukova L, Raevsky VV, (2011). Cellular neuropathology of absence epilepsy in the neocortex: a population of glial cells rather than neurons is impaired in genetic rat model. Acta Neurobiol Exp (Wars) 71: 263-268.
49. Somera-Molina KC, Robin B, Somera CA, Anderson C, Stine C, Koh S, et al. (2007). Glial activation links early-life seizures and long-term neurologic dysfunction: evidence using a small molecule inhibitor of proinflammatory cytokine upregulation. Epilepsia 48: 1785-1800.
50. Tanahashi S, Yamamura S, Nakagawa M, Motomura E, Okada M, (2012). Clozapine, but not haloperidol, enhances glial d-serine and L-glutamate release in rat frontal cortex and primary cultured astrocytes. Br J Pharmacol 165: 1543-1555.
51. Tian GF, Azmi H, Takano T, Xu Q, Peng W, Lin J, et al. (2005). An astrocytic basis of epilepsy. Nat Med 11: 973-981.
52. Timmerman W, Westerink BH, (1997). Brain microdialysis of GABA and glutamate: what does it signify? Synapse 27: 242-261.
53. Tolmacheva EA, van Luijtelaar G, (2007). Absence seizures are reduced by the enhancement of GABA-ergic inhibition in the hippocampus in WAG/Rij rats. Neurosci Lett 416: 17-21.
54. Vamos E, Pardutz A, Klivenyi P, Toldi J, Vecsei L, (2009). The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection. J Neurol Sci 283: 21-27.
55. Wetherington J, Serrano G, Dingledine R, (2008). Astrocytes in the epileptic brain. Neuron 58: 168-178.
56. White H, Woodhead J, Wilcox K, Stables J, Kupferberg H, Wolf H, (2002). Discovery and preclinical development of antiepileptic drugs. In:, Levy RH, Mattson RH, Meldrum BS, Perucca E, (eds). Antiepileptic Drugs, 5th edn. Lippincott Williams & Wilkins: Philadelphia, PA, pp. 36-48.
57. Yamamura S, Hamaguchi T, Ohoyama K, Sugiura Y, Suzuki D, Kanehara S, et al. (2009a). Topiramate and zonisamide prevent paradoxical intoxication induced by carbamazepine and phenytoin. Epilepsy Res 84: 172-186.
58. Yamamura S, Ohoyama K, Hamaguchi T, Nakagawa M, Suzuki D, Matsumoto T, et al. (2009b). Effects of zotepine on extracellular levels of monoamine, GABA and glutamate in rat prefrontal cortex. Br J Pharmacol 157: 656-665.
59. Yamamura S, Abe M, Nakagawa M, Ochi S, Ueno S, Okada M, (2011). Different actions for acute and chronic administration of mirtazapine on serotonergic transmission associated with raphe nuclei and their innervation cortical regions. Neuropharmacology 60: 550-560.